Clinical trials on cenicriviroc, a CC-chemokine receptor 2 (CCR2) antagonist, as a means to block CCL2 signaling, have shown significant improvements in relieving fibrosis progression with NASH (17). Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.